Загрузка...
Impact of genetic alterations on mTOR-targeted cancer therapy
Rapamycin and its derivatives (rapalogs), a group of allosteric inhibitors of mammalian target of rapamycin (mTOR), have been actively tested in a variety of cancer clinical trials, and some have been approved by the Food and Drug Administration for the treatment of certain types of cancers. However...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Sun Yat-sen University Cancer Center
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3845552/ https://ncbi.nlm.nih.gov/pubmed/23489586 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5732/cjc.013.10005 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|